Rh-Incompatibility-Induced Delayed Hemolytic Transfusion Reaction: Role of Immunologic Reactions in Rh-Incompatibility by Moshari, Mohammadreza et al.
  Journal of Cellular & Molecular Anesthesia (JCMA)  
Vol 3, No 2, Spring 2018 
81 
Case Report  
 
 
Rh-Incompatibility-Induced Delayed Hemolytic Transfusion 
Reaction: Role of Immunologic Reactions in RH-Incompatibility 
 
 




Blood transfusions cause to increase oxygen-carrying capacity and 
intravascular volume. Despite all the benefits of transfusion, it may have some 
complications. When mistransfusion occurs or when no other option is 
available, incompatible packed-cells may be infused, which puts the patient at 
risk of experiencing a hemolytic transfusion reaction (HTR). The HTRs are 
classified as acute or delayed reactions have wide spectrum of clinical 
presentations. In this report, we present a case of delayed hemolytic reaction 
due to rhesus factor (Rh) incompatibility in the operation room. Critical 
incident reporting and evaluation of adverse transfusion reactions may provide 
data for effective patient management and prevent the occurrence or repetition 
of these events.  
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In general, incompatible transfusions should be 
strictly avoided, as hemolysis of the transfused red 
blood cells (RBCs) can happen with potentially fatal 
outcomes, known as hemolytic transfusion reactions 
(Figure 1) (1).  
Clinical presentations of an incompatible 
transfusion cover a broad spectrum: in mild cases, the 
patients become immunized with alloantibodies 
bearing a potential risk for later transfusions or their 
pregnancies. Sometimes, serological tests become 
positive after the transfusion without any clinical 
presentations. In some other cases, the positive effect 
of the transfusion (e.g. rising of hemoglobin) is missing 
or too short lasting, but in a number of cases, severe or 
life-threatening events may occur (2). 
According to published statistics (2011-2015), 
about 14% of all deaths due to blood transfusion were 
related to non-ABO-dependent types (3-4). In fact, by 
implementing this process, the serum IgM levels 
increase sharply. This causes intravascular hemolysis, 
which ultimately ends in renal dysfunction, shock and 
death. Although immunoglobulin M hemolytic 
transfusion reactions (IgM-HTRs) have lower 
prevalence rates than HTRs (IgG-HTRs), the severity 
of degradation due to increased IgM-HTRs is more 
than other types (5-7). 
Antibody-induced hemolysis generally occurs 
by one of these two mechanisms; first, RBCs can be 
lysed intravascularly when complement is activated to 
form the Membrane Attack Complex (MAC). (8-11). 
This is usually due to IgM binding to the RBC 
membrane but can also occur with IgG (5-7). 
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Phagocytes can also opsonize the RBCs, a process 
called as extravascular hemolysis. If activation of 
complement does not lead to MAC formation to the 
extent that rapid intravascular hemolysis occurs, then 
C3 deposited on the RBC surface may convert to C3b 
and iC3b. In this case, Complement Receptors on 
phagocytes (i.e., CR1, CR2, and CR3) can consume 
C3b-coated RBCs. Second, antibody-induced 
opsonization can occur as a result of Fc domains of IgG 
bound to RBCs, which are recognized by Fcγ receptors 
(FcγRs) on phagocytes intravascularly (12-15). There 
is significant data mostly in animal models, which 
demonstrates the existence of each of these 
mechanisms of RBC clearance after binding to 
antibodies (8-11). 
Regardless of the canonical pathways described, 
alternative mechanisms of IgG-mediated RBC 
clearance have been suggested, which involve neither 
complement nor FcγR pathways. These include 
destabilization of the RBC membrane by antibody 
binding which can induce eryptosis (programmed RBC 
death) (12-18). 
Several in vitro investigations suggested that 
IgM and IgG antibodies interact with complement in 
different ways; it showed that one molecule of IgM on 
a cell surface is sufficient to initiate complement 
fixation, but a doublet (two molecules side by side) of 
the IgG in serum is required to form a complement-
fixing site. Nevertheless, electron microscopic and 
molecular studies have suggested that IgG antibody, 
although inefficient at initiating fixation of 
complement, may produce more membrane damage in 
comparison to IgM. Meanwhile, a series of cell surface 
receptors have been described which improve the 
adherence of antibody and complement-coated 
erythrocytes to macrophages and lymphocytes. 
Receptors specific for IgM, IgG and complement on 
macrophages and for complement on lymphocytes; 
these cellular receptors play an important role in both 
sequestration and clearance (19-23). 
Reporting the adverse transfusion reactions is 
not to find a guilty person but to reveal the cause of a 
transfusion reaction in order to treat the patient 
adequately and to prevent the occurrence or repetition 
of an adverse event (24). 
 
Clinical Report 
A 16-month old boy with left lateral neck mass 
(rhabdomyosarcoma) was brought to our operating 
room by the ear, nose, and throat (ENT) surgeons for 
palliative resection of the mass (Figure2). He had had 
the swelling of his left lateral neck for 9 months and 
underwent surgery in respect of the mass when he was 
11-month old which was diagnosed as 
rhabdomyosarcoma in pathological studies. It started 
to grow again and became 62*31*52 millimeters 




Figure 1. The patient with mandibular 
rhabdomyosarcoma. 
 
On preoperative assessment, the patient 
weighed 12 kilograms. No other problem was found in 
history and physical examination except for being 
passive-smoker. The anteroposterior and lateral neck 
X-ray showed intact airway with small deviation of 
trachea to the right side (Figure 3). His blood group and 
Rh was B-negative and laboratory data was within 




Figure 2. Anteroposterior and lateral neck X-ray. 
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Anesthesia induced using Sevoflurane 8% 
inhalation in oxygen; under basic monitoring 
(electrocardiogram, pulse oximetry, noninvasive blood 
pressure). Administering 0.25 mg atropine 
intravenously after about two minutes, the patient was 
successfully intubated in the first try by direct 
laryngoscopy using a #3.5 cuffed endotracheal tube. 
Then, 4 mg Atracurium and 25 microgram Fentanyl 
were infused through the intravascular (IV) line and 
maintenance of anesthesia was continued with 
Sevoflurane 2.5%. 
After 30 minutes of surgery, according to 
estimated blood loss (140 cc), we prescribed 20 cc of 
packed-cell for the infant. Soon after blood transfusion, 
blood bank informed us about sending the wrong unit 
of O-negative blood to the operation room. 
The transfusion was stopped. 200 mL of saline 
0.9% was administered over 15 minutes; Foley catheter 
was inserted,10 gr of mannitol was infused over 15 
minutes; 5 mg of Furosemide was injected; 10 mEq 
sodium bicarbonate was administered to alkalize the 
urine; the packed-cell and blood sample of patient was 
sent to the laboratory to repeat the crossmatch. Blood 
and urine samples were sent to the laboratory to check 
the blood cell count, partial thromboplastin time, 
fibrinogen level, direct coombs and urine analysis. 
Axillary temperature was 37.8ºC. 
Surgery lasted for about 90 minutes. He was 
extubated and taken to recovery when able to cry and 
according to lab results there was no hemoglobinuria, 
coagulation profile was normal and direct coombs was 
reported negative; but after six hours, the lab results 
were changed as below: 
Hemoglobin: 6.3 g/dL, Platelet: 307000, 
Hematocrit: 20%, Reticulin count: 0.2% 
(corrected=1%), partial thromboplastin time: 30, 
prothrombin time: 12, International Normalized Ratio: 
1.1, Urine Analysis: RBC: 3-5, pH 7.5, Hemoglobin: 
+, total Bilirubin: 0.6 mg/dL, direct Bilirubin direct: 
0.2 mg/dL, Direct coombs: negative, Lactate 
Dehydrogenase: 870 U/L, Fibrinogen: 190 mg/dL.  
Fifteen cc/Kg of iso-group and iso-Rh packed-
cell was infused over 4 hours and 5 mg of furosemide 
was prescribed. Three hours after transfusion 
hemoglobin concentration was 9 gr/dL and no 
hemoglobinuria were found in urine sample. All other 
lab data was normal. He was discharged in a stable 
condition two days later, after removing the drain and 
hemovac. In a weekly follow-up of our patient during 
the next 2 months, no serum antibodies appeared. 
Discussion 
Human error is a substantial factor in iatrogenic 
injury (1). Fortunately, most of these errors do not 
result in patient injury, but a small number can have 
catastrophic effects and lengthen the hospital stay. 
The reasons for mistransfusions may occur in 
the pre-analytical, laboratory and/or clinical periods of 
transfusion. Examples of pre-analytical errors are 
incorrect patient identification, donor mix-ups, and 
incorrect blood bag labelling. Laboratory errors may 
cause incorrect blood grouping or cross-matching. 
Clinical errors may happen at bedside testing or when 
the units are being transfused. Electronic data 
processing systems and various hemovigilance 
systems have been established during recent years to 
prevent these mistakes (25). 
Chiaroni et al, found that during a 5-year period 
in France, the incidence of ABO discrepancies was 1 
per 3,400 tests performed. In their experience, most 
discrepancies (58%) were secondary to phlebotomy 
errors in which the samples were obtained from the 
wrong patient, whereas the second common cause of 
discrepancy was error during patient registration (30%) 
(25). In comparison, in a study that Figueroa et al. have 
done, 90% of errors were due to patient identification 
at the time of phlebotomy, and only 10% were due to 
admission or registration errors (26). 
MacDougall and co-workers have attempted to 
mitigate the risk of ABO mismatch associated with 
knowledge gap. Based on the findings, they found that 
the use of adaptive methods (for blood compatibility in 
ABO system) is helpful in blood donors and recipients. 
In fact, this can be done as a “forcing function” before 
the release of blood from the blood bank and before 
transfusion at the bedside to reduce transfusion 
mismatch associated with gaps in ABO compatibility 
knowledge especially in Fresh Frozen Plasma and 
Platelet transfusion (25). 
Some options include easy access to standard 
operating procedure instructions in work areas (25), a 
blood-component lock system that will not allow the 
issuance of a component unless there is a patient 
wristband and blood component match (26), and 
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computerized inventory control that will not permit 
issuance of a blood component that does not match the 
written request. Ultimately, automation may be the 
best solution. Handheld bar-code devices that may be 
used at the bedside can prevent the need for visual 
matching of data (26-28). 
Ahrens et al. reported that of 21 transfusion-
related errors, one (4.8%) was a pre-analytical error, 4 
(19.0%) were laboratory errors and 16 (76.2%) were 
clinical errors (28). Their results confirm that bedside 
testing is the weakest link in the safety chain of 
transfusion in medical practice (26-29). 
Delayed hemolytic transfusion reactions have 
been studied widely in the setting of sickle cell disease 
and beta-thalassemia, emphasizing the risk of adverse 
events in patients with baseline hematologic 
deficiencies (26-29). Chadebech et al, reported two 
cases of sickle cell disease with delayed hemolytic 
transfusion reaction in the absence of detectable 
antibody. Even in monthly follow-up of the serum of 
these patients in 6 months, no antibodies appeared (26). 
Within the pediatric population, allergic 
reactions to platelets and RBCs were the most common 
reported reaction types. As said by Vossoughi et al. the 
rate of allergic reactions to platelets was more than 
three times, and the rate of allergic reactions to RBCs 
was more than seven times the adult rate (26). 
Irani et al, reported a case of a delayed 
hemolytic transfusion reaction due to anti-e, an antigen 
in the Rh blood group system, after a liver transplant 
that was a consequence of receiving emergent 
incompatible RBC transfused during surgery that was 
treated successfully using an automated red cell 
exchange. According to this study, they stated that how 
a red cell exchange can reduce the potentially harmful 
effects of a delayed hemolytic transfusion reaction 
caused by anti-e or any clinically significant red blood 
cell antibody (26). 
Werch et al, reported two women in child 
bearing age who had D2 blood type and received two 
units of D1 RBCs. Prompt delivery of intravenous 
RHIG (Rh Immunoglobulin) prophylaxis could 
prevent alloimmunization and associated 
complications in those two patients (27). 
Arneja et al, have combined a recently 
developed mouse model for transfusion mediated RBC 
alloimmunization with mice genetically deficient in 
interleukin-6 receptor (IL-6Rα) to determine the role 
of IL-6Rα signaling in regulating RBC 
alloimmunization. The findings indicated that IL-6Rα 
signaling plays a key role in the generation of anti-
RBC alloantibodies in response to transfused RBCs. 
Based on these results, available biologics targeting IL-
6Rα can be a therapeutic option for the prevention of 
RBC alloimmunization (27). 
While much remains to be learned, better 
concept of the cellular and molecular mechanisms that 
govern the course of HTRs, will undoubtedly lead to 
better therapy and improved survival for patients 
suffering this life-threatening complication of 
transfusion and shorten the duration of their hospital 
stay. 
Conclusion 
   By decreasing the incidence of human errors we can 
prevent complications of mistransfusion. There are so 
many unknown aspects of cellular and molecular 
pathophysiology of mistransfusion which could be a 
good target for future researches. By preventing human 
errors and improving our knowledge and skill to face 
these kind of complications, we can hopefully improve 
survival of our patients. 
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